MPAM
ANIP icon

Monarch Partners Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Monarch Partners Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,910
Closed -$358K – 171
2019
Q3 		$358K Buy
4,910
+580
+13% +$43.4K 0.05% 162
2019
Q2 		$356K Sell
4,330
-770
-15% -$54.8K 0.05% 158
2019
Q1 		$360K Buy
+5,100
New +$300K 0.05% 164

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Monarch Partners Asset Management's ANIP Position: Q4 2019 in Review

Monarch Partners Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2019, closing a stake of 4,910 shares — an estimated $358K sold.

Monarch Partners Asset Management first reported a position in ANIP in Q1 2019 and held it in 3 quarters. The position peaked at $360K in Q1 2019. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

  • Monarch Partners Asset Management reported no remaining ANI Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Monarch Partners Asset Management sold 4,910 ANI Pharmaceuticals shares in Q4 2019, an estimated $358K.
  • Monarch Partners Asset Management first reported a position in ANI Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Monarch Partners Asset Management's ANI Pharmaceuticals position peaked at $360K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Monarch Partners Asset Management's 13F filing for Q4 2019, filed 5 Feb 2020.